Geoffrey W. Levin

GEOFF LEVIN concentrates his practice on growth equity and venture investments in the life sciences and other complex business transactions and governance matters for private equity sponsors and their portfolio companies. Geoff has more than 30 years of experience representing clients across a number of industries in a variety of transactional matters, including domestic and cross-border M&A, leveraged buyouts, going private transactions, public and private securities offerings, proxy contests, spin-offs, joint ventures, recapitalizations, venture capital financing, growth equity investments, PIPEs, debt financings, restructurings, and workouts.

Geoff’s representations have covered a broad range of industries including life sciences, financial services, communications, energy, retail, automotive and heavy industrial.

Geoff regularly comments on developments in the healthcare industry and speaks at investment conferences and spearheaded a series of webinars on healthcare and life sciences topics for private equity investors. He is listed by IFLR 1000 as a leading M&A lawyer and has been recognized by Institutional Investor News as one of the “10 Rising Stars of Private Equity and M&A Law” and by Mergermarket as a “Dealmaker of the Year.”

Prior to joining Sidley, Geoff was a partner at another global law firm. Geoff received his J.D., magna cum laude and Order of the Coif, from the University of Minnesota, where he was executive editor of the Journal of International Economic Law & Policy, and a B.B.A., with high distinction, from the University of Michigan. He is admitted to practice in the State of New York.

Joint-Ventures/Growth Equity/Venture Capital Investments

• OrbiMed and RA Capital Management on their investment in Verdiva Bio Limited’s US$411 million Series A financing.
• Arsenal Capital Partners in its investment in Epic Sciences
• OrbiMed funds in more than one hundred investments in domestic and multinational life sciences companies
• Tricida, Inc. in its $42 million registered direct equity financing
• D1 Capital as lead investor in more than a dozen growth equity investments in healthcare, life sciences and med-tech companies
• Redmile Group as lead investor in more than a dozen growth equity investments in healthcare, life sciences and med-tech companies
• Private investment funds in over US$500 million of PIPE financings
• Aprea Therapeutics, Inc. in its US$98 million initial public offering of common stock and EUR 50 million Series C Financing
• Tricida, Inc. with its US$200 million convertible notes offering, US$230 million follow-on common stock offering, and US$255 million IPO as well as the extension and expansion of its US$200 million credit facility
• Paine Schwartz Partners, LLC, a global leader in sustainable food chain investing, in its strategic investment through its Paine Schwartz Food Chain Fund IV in MS Biotech Holdings, Inc., a provider of natural, proprietary products to the beef feedlot and dairy markets.
• Cerapedics, a privately held orthobiologics company, in multiple rounds of debt and equity financing
• Tricida, Inc. in its US$57.5 million Series D and US$55 million Series C financings
• New Leaf Venture Partners in its investment in Harpoon Therapeutics’ US$45 million Series B financing
• CVC Capital as a Founding Investor in Fidelis Insurance Holdings Limited, a Bermuda-based specialty insurance company
• An investment fund in a US$100 million funding commitment and joint venture arrangements for an online gaming start-up

Mergers & Acquisitions and Corporate Governance

• Aprea Therapeutics in its acquisition of Atrin Pharmaceuticals Inc. via reverse merger
• Bridger Aerospace Group Holdings, LLC in business combination with SPAC Jack Creek Investment Corp.
• Two Sigma Securities in the acquisition of the U.S. options-market-making business of Timber Hill, a subsidiary of Interactive Brokers Group
• Novira Therapeutics, a clinical-stage biopharma company developing novel viral therapeutic candidates, in its sale to Johnson & Johnson
• Chinese Manufacturer in its bid to acquire a U.S. OEM automotive supplier
• Broker Dealer in its acquisition of an options market maker
• The Management Team of Medpace in its US$900 million acquisition by Cinven
• Vertis Holdings in its US$363 million sale to Quad/Graphics
• Icahn Capital in its bid for Blockbuster, Inc.
• ZS Fund in the acquisition of SOS Security
• CVC Capital Partners in its US$4.4 billion agreement (terminated) to acquire the iShares ETF business from Barclays
• The U.S. Treasury in the Chrysler restructuring
• CVC Capital Partners in its US$2.3 billion take private acquisition of Univar N.V.
• Lyondell Chemical Company in the equity backstop by Apollo, Ares and Access Industries of a US$2.8 billion rights offering

*Includes matters that were handled by Geoff prior to joining Sidley.

Geoff is a member of the National Leadership Council of AFINS (American Friends of Israel Navy SEALS) and is on the Board of Trustees of the Silverstein Foundation for Parkinson’s with GBA.